Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Offering SPR-BLI Services - Proteins provided for free! 
Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Thank you for choosing ACROBiosystems. Would you rate our product and service？Thank you for choosing ACROBiosystems. Would you rate our product and service？
1. EED as a promising therapeutic target
(1) Dysregulations in polycomb repressive complex 2 (PRC2) have been found in a number of human cancers. PRC2 compromises four components, EED is a critical component of PRC2 complex and mediates allosteric activation of EZH2 by H3K27me3.
(2) EED inhibitor might overcome the long-term resistance of EZH2 inhibitors
- EED inhibition manifests comparable effects of EZH2 inhibition
- EED inhibition is not affected by EZH2 acquired resistant mutations
- EED inhibition also has an effect on EZH1, which has comparable function as EZH2, and maybe compensatively up-regulation while EZH2 inhibition
(3) EED inhibitor has the potential to treat advanced malignancies for whom no effective standard treatment is available.
(4) PRC2 inhibition profoundly modulates immune system, especially in T cell and tumor microenvironment, which provides strong rationale for combination trials with other immuno-therapies for blood cancer and solid tumor.
(5) EZH2 inhibitors face the risk of secondary toxicity, EED inhibitor could be a substitutional option for patients
2. A novel EED inhibitor with favorable features
(1) Asset vs MAK683
- Better drug-like properties (solubility, free plasma concentration)
- Better PK profiles (exposure) across species
- Comparable efficacy of tumor regression
- Potential better tolerability in toxicological study
(2) Asset vs EPZ6438
- Shows activity on EZH2-inhibitor Resistant Cell line
- Better efficacy of tumor regression
(3) Asset exhibits excellent efficacy in vivo: strong and complete tumor regression at 10 mpk BID on Karpas422 CDX model, with TGI 98.4%
Note:
MAK683 is an investigational EED inhibitor developed by Novartis
EPZ6438 is an approved first-in-class EZH2 inhibitor developed by Epizyme
1. Asset type: ActRIIB inhibitor
2. Indication: Cancer cachexia
3. Modality:Small molecule
4. Research:Pre-clinical
5. Demands： License-out or co-development
Research progress:
IND approved by FDA and NMPA
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
This web search service is supported by Google Inc.
A-Z
